|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001792,
umls-concept:C0008976,
umls-concept:C0079083,
umls-concept:C0144576,
umls-concept:C0205195,
umls-concept:C0332293,
umls-concept:C0684249,
umls-concept:C0796392,
umls-concept:C0936012,
umls-concept:C1274040,
umls-concept:C1512162,
umls-concept:C1516213,
umls-concept:C1518422
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-31
|
|
pubmed:abstractText |
Fit elderly patients with advanced non-small-cell lung cancer (NSCLC) benefit from platinum-based, two-drug chemotherapy. Bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) improves survival for advanced, nonsquamous NSCLC, as evidenced in Eastern Cooperative Oncology Group (ECOG) 4599. We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
60-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18165641-Adenocarcinoma,
pubmed-meshheading:18165641-Aged,
pubmed-meshheading:18165641-Antibodies, Monoclonal,
pubmed-meshheading:18165641-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18165641-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18165641-Carboplatin,
pubmed-meshheading:18165641-Carcinoma, Large Cell,
pubmed-meshheading:18165641-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18165641-Female,
pubmed-meshheading:18165641-Humans,
pubmed-meshheading:18165641-Lung Neoplasms,
pubmed-meshheading:18165641-Male,
pubmed-meshheading:18165641-Neoplasm Staging,
pubmed-meshheading:18165641-Paclitaxel,
pubmed-meshheading:18165641-Prognosis,
pubmed-meshheading:18165641-Survival Rate
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
|
|
pubmed:affiliation |
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA. suresh.ramalingam@emory.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
